A New Millennium In The Antipsychotic Treatment Of Patients With Bipolar Disorder
Paper Symposium
Activity Date: December 15 2004 — Activity Info: Volume 4, (10F)
 

Full Disclosure Policy Affecting CME Activities:
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of Johns Hopkins University School of Medicine to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Program Directors and Participating Faculty reported the following:

PROGRAM DIRECTORS

Jennifer L. Payne, MD
Assistant Professor
Department of Psychiatry and Behavioral Sciences
Johns Hopkins UniversitySchool of Medicine
Baltimore, Maryland
Dr Payne reports receiving grants/research support from the National Alliance for Research on Schizophrenia and Depression and Stanley Medical Research Institute.

Rajiv Tandon, MD
Chief of Psychiatry
Florida Department of Children and Families
Tallahassee, Florida
Dr Tandon reports serving as a consultant to AstraZeneca LP, Bristol-Myers Squibb Company, Eli Lilly and Company, Janssen Pharmaceutica, and Pfizer Inc.

PARTICIPATING FACULTY

Peter F. Buckley, MD
Professor and Chairman
Department of Psychiatry and Health Behavior
Medical College of Georgia
Augusta, Georgia
Dr Buckley reports receiving grants/research support from AstraZeneca LP, Bristol-Myers Squibb Company, Eli Lilly and Company, Janssen Pharmaceutica, Novartis Pharmaceuticals USA, Pfizer Inc, and Solvay SA; serving as a consultant to and receiving honoraria from Abbott Laboratories, Alamo Pharmaceuticals, AstraZeneca LP, Bristol-Myers  Squibb Company, Eli Lilly and Company, Janssen Pharmaceutica, Novartis Pharmaceuticals USA, Pfizer Inc, and Pharmstar Ltd; and serving on the speakers' bureaus for Abbott Laboratories, AstraZeneca LP, Bristol-Myers Squibb Company, Eli Lilly and Company, Janssen Pharmaceutica, Novartis Pharmaceuticals USA, and Pfizer Inc.

Robert L. Findling, MD
Professor
Departments of Psychiatry and Pediatrics
University Hospitals of Cleveland/Case Western Reserve University
Cleveland, Ohio
Dr Findling reports receiving grants/research support from Abbott Laboratories, AstraZeneca LP, Bristol-Myers Squibb Company, Celltech Group, Eli Lilly and Company, Forest Laboratories, Inc, GlaxoSmithKline, Johnson & Johnson, Novartis Pharmaceuticals USA, Otsuka America Pharmaceutical, Inc, Pfizer Inc, Shire Pharmaceuticals Group, Solvay SA, and Wyeth; serving as a consultant to Abbott Laboratories, AstraZeneca LP, Best Practices, Bristol-Myers Squibb Company, Celltech Group, Eli Lilly and Company, Forest Laboratories, Inc, GlaxoSmithKline, Johnson & Johnson, New River Pharmaceuticals Inc, Novartis Pharmaceuticals USA, Noven Pharmaceuticals, Otsuka America Pharmaceutical, Inc, Pharmaceutical Product Development, Inc, Pfizer Inc, Shire Pharmaceuticals Group, and Wyeth; and serving on the speakerÕs bureaus for Abbott Laboratories, AstraZeneca LP, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Otsuka America Pharmaceutical, Inc, Shire Pharmaceuticals Group, and Wyeth.

Jeffrey Lieberman, MD
Vice Chair of Psychiatry
Department of Psychiatry
University of North CarolinaSchool of Medicine
Chapel Hill, North Carolina
Dr Lieberman reports receiving grants/research support from AstraZeneca LP, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline, Janssen Pharmaceutica, Novartis Pharmaceuticals USA, Organon, Pfizer Inc, and Sanofi-Synthelabo Inc; serving as a consultant to AstraZeneca LP, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Novartis Pharmaceuticals USA, Pfizer Inc, and Solvay SA; and serving on the advisory boards for AstraZeneca LP, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline, Organon, Pfizer Inc, and Solvay SA.

Diana O. Perkins, MD, MPH
Professor
Department of Psychiatry
University of North Carolina School of Medicine
Chapel Hill, North Carolina
Dr Perkins reports receiving grants/research support from AstraZeneca LP, Bristol-Myers Squibb Company, Eli Lilly and Company, Otsuka America Pharmaceutical, Inc, and Pfizer Inc; and serving as a consultant to Bristol-Myers Squibb Company.

Notice: In accordance with the ACCME Standards for Commercial Support, the audience is advised that one or more articles in this continuing medical education activity may contain reference(s) to unlabeled or unapproved uses of drugs or devices. The following faculty members have disclosed that their articles have referenced the following unlabeled/unapproved uses of drugs or devices:

Dr Buckley—carbamazepine, clozapine, divalproex, gabapentin, oxcarbazepine, tiagabin, topiramate, zonisamide.
Dr Findling—arbamazepine, clozapine, divalproex, lamotrigine.
Dr Lieberman—clozapine, divalproex, fluoxetine, fluvoxamine, risperidone.

All other faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs or devices.

Advanced Studies in Medicine provides disclosure information from contributing authors, lead presenters, and participating faculty. Advanced Studies in Medicine does not provide disclosure information from authors of abstracts and poster presentations. The reader shall be advised that these contributors may or may not maintain financial relationships with pharmaceutical companies.

 
 
     
 
Home | Contact Us | View Account | Need Help?